Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DH7ZV4
|
|||
| Drug Name |
JNJ-75348780
|
|||
| Drug Type |
Bispecific antibody
|
|||
| Indication | Chronic lymphocytic leukaemia [ICD-11: 2A82.0; ICD-10: C83.0, C91.1] | Phase 1 | [1] | |
| Non-hodgkin lymphoma [ICD-11: 2B33.5; ICD-10: C82-C85; ICD-9: 200, 202] | Phase 1 | [1] | ||
| Company |
JOHNSON & JOHNSON
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | B-cell receptor CD22 (CD22) | Target Info | . | [1] |
| T-cell surface glycoprotein CD3 (CD3) | Target Info | . | [1] | |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| Hematopoietic cell lineage | ||||
| B cell receptor signaling pathway | ||||
| Panther Pathway | B cell activation | |||
| Pathway Interaction Database | BCR signaling pathway | |||
| Reactome | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | ||||
| WikiPathways | B Cell Receptor Signaling Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04540796) A Phase 1, First-in-Human, Dose Escalation Study of the JNJ-75348780 Bispecific Antibody Targeting CD3 and CD22 in Participants With NHL and CLL. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.